Addex Therapeutics Ltd (ADXN)
ADXN Stock Price Chart
Explore Addex Therapeutics Ltd interactive price chart. Choose custom timeframes to analyze ADXN price movements and trends.
ADXN Company Profile
Discover essential business fundamentals and corporate details for Addex Therapeutics Ltd (ADXN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Feb 2020
Employees
2.00
CEO
Timothy Mark Dyer
Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
ADXN Financial Timeline
Browse a chronological timeline of Addex Therapeutics Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Apr 2026
Upcoming earnings on 10 Nov 2025
Earnings released on 20 Jun 2025
EPS came in at -$1.33 surpassing the estimated -$4.26 by +68.77%.
Earnings released on 25 Apr 2025
EPS came in at -$1.37 falling short of the estimated -$0.01 by -13.60K%, while revenue for the quarter reached $1.66K , missing expectations by -99.17%.
Earnings released on 22 Nov 2024
EPS came in at -$2.77 falling short of the estimated -$1.40 by -97.86%, while revenue for the quarter reached $62.72K , missing expectations by -58.18%.
Earnings released on 30 Sept 2024
EPS came in at -$1.77 falling short of the estimated -$0.01 by -17.60K%, while revenue for the quarter reached $128.66K , missing expectations by -50.52%.
Earnings released on 6 Jun 2024
EPS came in at -$1.37 falling short of the estimated -$0.44 by -210.28%, while revenue for the quarter reached $259.41K , missing expectations by -66.43%.
Earnings released on 4 Apr 2024
EPS came in at $5.00 surpassing the estimated -$4.00 by +225.00%, while revenue for the quarter reached $179.34K , missing expectations by -76.79%.
Earnings released on 29 Nov 2023
EPS came in at -$4.07 falling short of the estimated -$4.00 by -1.75%, while revenue for the quarter reached $357.33K , missing expectations by -46.05%.
Stock split effective on 23 Oct 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Aug 2023
EPS came in at -$5.00 falling short of the estimated -$0.83 by -506.00%, while revenue for the quarter reached $703.35K , beating expectations by +127.32%.
Earnings released on 11 May 2023
EPS came in at -$5.20 falling short of the estimated -$1.03 by -404.19%, while revenue for the quarter reached $546.62K , beating expectations by +76.67%.
Earnings released on 30 Mar 2023
EPS came in at -$5.00 falling short of the estimated -$1.03 by -384.80%, while revenue for the quarter reached $640.56K , beating expectations by +148.43%.
Earnings released on 11 Nov 2022
EPS came in at -$11.20 matching the estimated -$11.20, while revenue for the quarter reached $416.06K , beating expectations by +79.29%.
Earnings released on 18 Aug 2022
EPS came in at -$23.60 falling short of the estimated -$11.20 by -110.71%, while revenue for the quarter reached $191.40K , missing expectations by -63.94%.
Earnings released on 5 May 2022
EPS came in at -$19.40 falling short of the estimated -$10.40 by -86.54%, while revenue for the quarter reached $256.26K , missing expectations by -49.31%.
Earnings released on 10 Mar 2022
EPS came in at -$16.60 falling short of the estimated -$13.20 by -25.76%, while revenue for the quarter reached $434.68K , missing expectations by -15.60%.
Earnings released on 4 Nov 2021
EPS came in at -$14.40 matching the estimated -$14.40, while revenue for the quarter reached $732.50K , beating expectations by +7.40%.
Earnings released on 5 Aug 2021
EPS came in at -$15.40 falling short of the estimated -$13.00 by -18.46%, while revenue for the quarter reached $1.07M , beating expectations by +32.76%.
Earnings released on 5 May 2021
EPS came in at -$10.60 surpassing the estimated -$13.00 by +18.46%, while revenue for the quarter reached $896.30K .
Earnings released on 11 Mar 2021
EPS came in at -$10.60 , while revenue for the quarter reached $2.06M .
Earnings released on 3 Nov 2020
EPS came in at -$15.60 , while revenue for the quarter reached $29.65K .
ADXN Stock Performance
Access detailed ADXN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.